Search Results

You are looking at 1 - 10 of 62 items for :

  • "testicular cancer" x
Clear All
Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang and Richard B. Wilder

Overview An estimated 8590 new cases of testicular cancer will be diagnosed in the United States in 2012. 1 Germ cell tumors (GCTs) constitute 95% of malignant tumors arising in the testes. These tumors also occur occasionally in extragonadal

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

estimated 8,430 new cases of testicular cancer will be diagnosed in the United States in 2015. 1 Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes. These tumors also occur occasionally in extragonadal primary sites, but they are

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld and Jue Wang

the express written permission of the NCCN © 2009. Disclosures for the NCCN Testicular Cancer Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry

Full access

Chunkit Fung, Sophie D. Fossa, Clair J. Beard and Lois B. Travis

Testicular cancer (TC) is the most common cancer among men aged 18 to 39 years, 1 with a worldwide doubling in incidence over the past few decades. 2 In contrast to the poor survival associated with many young adult cancers, the 5- and 10-year

Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa and Lois B. Travis

Although the incidence of testicular cancer (TC) continues to increase globally, 1 TC mortality has declined, 1 attributable in large part to cisplatin-based chemotherapy. 2 Due to the 10-year relative survival rate approaching 95%, 3 treatment

Full access

Linda A. Jacobs and David J. Vaughn

Testicular cancer (TC) is the most common cancer of men in their 20s and 30s. TC is considered the model of a curable neoplasm and constitutes one of the greatest success stories in modern medicine since the advent of effective multiagent

Full access

Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis and for the Platinum Study Group

Background Testicular cancer is the most common cancer among young men (age 18–39 years). 1 Currently, >95% of patients are cured of the disease. 2 Although some patients with stage I disease are cured with orchiectomy only, those with advanced or

Full access

The UNMC Eppley Cancer Center at The Nebraska Medical Center

An estimated 8250 new cases of testicular cancer will be diagnosed in the United States in 2006, with germ cell tumors (GCTs) constituting 95% of the malignant tumors arising in the testes. Although GCTs are relatively uncommon tumors, they are the most common solid tumor in men between the ages of 15 and 34 years. The worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCTs are cured, including 70% to 80% of patients with advanced tumors who are treated with chemotherapy. Standard therapy has been established at essentially all stages of management and must be closely followed to ensure the potential for cure.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld and Darren R. Feldman

Testicular cancer is the most common cancer in men aged 15 to 40 years in the United States, Canada, and many European countries. 1 , 2 The incidence of testicular cancer is increasing in all of these areas, and in several countries it has

Full access

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller and Lenora A. Pluchino

Overview Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. 1 However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past